Choong Ang Vaccine Laboratory Co (072020) Fair Value & Analysis
Healthcare · KR · Market cap 85.8B KRW
Fair value as of: Jul 22, 2026
From 24 valuation models · updated 19 days ago
Fair value updated Jul 22, 2026, revised from 7,741 KRW to 7,826 KRW (+1.1%) since Jul 6, 2026. Share price −0.5% over the past month.
A solid business, but screening 16% overvalued on our models.
What matters now
- Solid but not exceptional quality (63/100) and above fair value, neither a clear bargain nor a standout compounder.
- Our model range runs from 5,752 KRW (bear) to 9,900 KRW (bull), base 7,826 KRW. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 63/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 8,669 KRW – 18,052 KRW · fair‑value band 5,752 KRW – 9,900 KRW · the 9,300 KRW price screens above the 7,826 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Choong Ang Vaccine Laboratory Co (072020) currently trades at 9,300 KRW, while our model-based Fair Value estimate is 7,826 KRW, implying the stock looks roughly 15.9% overvalued today. The Quality Score stands at 63/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Choong Ang Vaccine Laboratory Co generated revenue of 39.2B KRW at a net margin of 9.3%. Revenue declined 1.1% year over year. It earns a return on equity of 3.8%. Net debt stands at 4.4B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 5,752 KRW (bear case) to 9,900 KRW (bull case); at 9,300 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 10% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -16%, 072020 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (8,501 KRW) versus Earnings-Based (3,997 KRW). Highest evidence: Growth DCF (80).
Notify me when 072020 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 61 · Market factors (momentum, volatility) 52
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Choong Ang Vaccine Laboratory Co., Ltd. engages in the research, development, manufacturing, and sale of animal vaccines in South Korea, Asia, Africa, and the United States. It offers swine, poultry, cattle, canine, feline, wild boar, and raccoon vaccines under the SuiShot, PoulShot, BoviShot, CaniShot, and FeliShot brands.
Full company description
Choong Ang Vaccine Laboratory Co., Ltd. engages in the research, development, manufacturing, and sale of animal vaccines in South Korea, Asia, Africa, and the United States. It offers swine, poultry, cattle, canine, feline, wild boar, and raccoon vaccines under the SuiShot, PoulShot, BoviShot, CaniShot, and FeliShot brands. The company was founded in 1968 and is headquartered in Daejeon, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Choong Ang Vaccine Laboratory Co reported revenue of 49.1B KRW in FY2025 versus 40.9B KRW in FY2021, a compound +4.6%/yr. Reported net income was 6.2B KRW in FY2025, compounding −5.1%/yr from FY2021.
072020 screens 16% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Choong Ang Vaccine Laboratory Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Choong Ang Vaccine Laboratory Co (072020) overvalued or undervalued?
What is the fair value of 072020?
What is the quality score of 072020?
What is the revenue of Choong Ang Vaccine Laboratory Co (072020)?
What is the net profit margin of 072020?
Does Choong Ang Vaccine Laboratory Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Choong Ang Vaccine Laboratory Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.